These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36444328)

  • 1. Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement.
    Li JJ; Ma CS; Zhao D; Yan XW;
    JACC Asia; 2022 Nov; 2(6):653-665. PubMed ID: 36444328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease.
    Nestel P; Loh WJ; Ward NC; Watts GF
    J Clin Endocrinol Metab; 2022 Nov; 107(11):e4281-e4294. PubMed ID: 36108076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque.
    Ooi EM; Ellis KL; Barrett PHR; Watts GF; Hung J; Beilby JP; Thompson PL; Stobie P; McQuillan BM
    Atherosclerosis; 2018 Aug; 275():232-238. PubMed ID: 29960898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.
    Nsaibia MJ; Mahmut A; Boulanger MC; Arsenault BJ; Bouchareb R; Simard S; Witztum JL; Clavel MA; Pibarot P; Bossé Y; Tsimikas S; Mathieu P
    J Intern Med; 2016 Nov; 280(5):509-517. PubMed ID: 27237700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
    Kronenberg F; Mora S; Stroes ESG; Ference BA; Arsenault BJ; Berglund L; Dweck MR; Koschinsky M; Lambert G; Mach F; McNeal CJ; Moriarty PM; Natarajan P; Nordestgaard BG; Parhofer KG; Virani SS; von Eckardstein A; Watts GF; Stock JK; Ray KK; Tokgözoğlu LS; Catapano AL
    Eur Heart J; 2022 Oct; 43(39):3925-3946. PubMed ID: 36036785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and In Vitro Inhibition of
    Perrot N; Valerio V; Moschetta D; Boekholdt SM; Dina C; Chen HY; Abner E; Martinsson A; Manikpurage HD; Rigade S; Capoulade R; Mass E; Clavel MA; Le Tourneau T; Messika-Zeitoun D; Wareham NJ; Engert JC; Polvani G; Pibarot P; Esko T; Smith JG; Mathieu P; Thanassoulis G; Schott JJ; Bossé Y; Camera M; Thériault S; Poggio P; Arsenault BJ
    JACC Basic Transl Sci; 2020 Jul; 5(7):649-661. PubMed ID: 32760854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.
    Gilliland TC; Liu Y; Mohebi R; Miksenas H; Haidermota S; Wong M; Hu X; Cristino JR; Browne A; Plutzky J; Tsimikas S; Januzzi JL; Natarajan P
    J Am Coll Cardiol; 2023 May; 81(18):1780-1792. PubMed ID: 37137588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
    Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
    Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA).
    Chiesa G; Zenti MG; Baragetti A; Barbagallo CM; Borghi C; Colivicchi F; Maggioni AP; Noto D; Pirro M; Rivellese AA; Sampietro T; Sbrana F; Arca M; Averna M; Catapano AL
    Nutr Metab Cardiovasc Dis; 2023 Oct; 33(10):1866-1877. PubMed ID: 37586921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
    Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
    Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidized phospholipids and lipoprotein-associated phospholipase A
    Tselepis AD
    J Biomed Res; 2018 Jan; 31(1):13-22. PubMed ID: 27346583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DIAGNOSIS AND TREATMENT OF ELEVATED LIPOPROTEIN(A) IN ISRAEL: CONSENSUS STATEMENT FROM THE ISRAEL SOCIETY FOR RESEARCH, PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND ISRAEL SOCIETY FOR CLINICAL LABORATORY SCIENCES].
    Zafrir B; Durst R; Henig C; Henkin Y; Itzhakov E; Kaplan M; Gavish D
    Harefuah; 2024 Mar; 163(3):185-190. PubMed ID: 38506362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.
    Vinci P; Di Girolamo FG; Panizon E; Tosoni LM; Cerrato C; Pellicori F; Altamura N; Pirulli A; Zaccari M; Biasinutto C; Roni C; Fiotti N; Schincariol P; Mangogna A; Biolo G
    Int J Environ Res Public Health; 2023 Sep; 20(18):. PubMed ID: 37754581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.
    Makover ME; Shapiro MD; Toth PP
    Am J Prev Cardiol; 2022 Dec; 12():100371. PubMed ID: 36124049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.